# Special Issue

# Cystic Fibrosis: Diagnosis, Treatment, and Related Disorders

## Message from the Guest Editors

Over the last decade, major clinical advances have been achieved in delaying cystic fibrosis (CF) progress with the implementation of newborn screening programs and development of novel therapies, including CFTR modulator drugs. Assessment of CFTR function and response to modulator drugs in CF carriers who present with CFTR-related disorders is warranted. Many novel assays and models have emerged to better understand the genotype–phenotype relationship and to predict drug effectiveness in a personalized medicine approach. In parallel, mutation-agnostic therapies (i.e., independent of CFTR mutation) are under development. This Special Issue on "Cystic Fibrosis" aims to gather a collection of reviews and original articles focused on "Diagnosis, Treatment, and Related Disorders" to this disease at basic, translational, and clinical levels to provide expert insights and perspectives on advances in the field.

## Guest Editors

Dr. Miquéias Lopes-Pacheco

Dr. Neeraj Sharma

Dr. Shafagh Waters

## Deadline for manuscript submissions

closed (10 August 2023)

**Journal of Personalized Medicine**

**an Open Access Journal by MDPI**

**CiteScore 6.0**
**Indexed in PubMed**

mdpi.com/si/92074

*Journal of Personalized Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

MDPI

# About the Journal

## Message from the Editor-in-Chief

*Journal of Personalized Medicine* (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

## Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

## Author Benefits

**High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

**Journal Rank:**

CiteScore - Q1 (Medicine (miscellaneous))

**Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).